Abstract

SMNDC1 is a Tudor domain protein that recognizes di-methylated arginines and controls gene expression as an essential splicing factor. Here, we study the specific contributions of the SMNDC1 Tudor domain to protein-protein interactions, subcellular localization, and molecular function. To perturb the protein function in cells, we develop small molecule inhibitors targeting the dimethylarginine binding pocket of the SMNDC1 Tudor domain. We find that SMNDC1 localizes to phase-separated membraneless organelles that partially overlap with nuclear speckles. This condensation behavior is driven by the unstructured C-terminal region of SMNDC1, depends on RNA interaction and can be recapitulated in vitro. Inhibitors of the protein’s Tudor domain drastically alter protein-protein interactions and subcellular localization, causing splicing changes for SMNDC1-dependent genes. These compounds will enable further pharmacological studies on the role of SMNDC1 in the regulation of nuclear condensates, gene regulation and cell identity.

SMNDC1 is a splicing factor that binds arginine methylation with its Tudor domain. Here, the authors study the protein’s phase-separating behavior and develop small-molecule Tudor domain inhibitors that perturb SMNDC1 function.

Details

Title
Pharmacological perturbation of the phase-separating protein SMNDC1
Author
Enders, Lennart 1   VIAFID ORCID Logo  ; Siklos, Marton 1 ; Borggräfe, Jan 2 ; Gaussmann, Stefan 3   VIAFID ORCID Logo  ; Koren, Anna 1 ; Malik, Monika 1 ; Tomek, Tatjana 1 ; Schuster, Michael 1   VIAFID ORCID Logo  ; Reiniš, Jiří 1 ; Hahn, Elisa 1   VIAFID ORCID Logo  ; Rukavina, Andrea 1 ; Reicher, Andreas 1 ; Casteels, Tamara 4 ; Bock, Christoph 5   VIAFID ORCID Logo  ; Winter, Georg E. 1   VIAFID ORCID Logo  ; Hannich, J. Thomas 1 ; Sattler, Michael 2   VIAFID ORCID Logo  ; Kubicek, Stefan 1   VIAFID ORCID Logo 

 CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria (GRID:grid.418729.1) (ISNI:0000 0004 0392 6802) 
 Institute of Structural Biology, Helmholtz Munich, Molecular Targets and Therapeutics Center, Neuherberg, Germany (GRID:grid.418729.1); Technical University of Munich, TUM School of Natural Sciences, Department of Bioscience, Bavarian NMR Center, Garching, Germany (GRID:grid.6936.a) (ISNI:0000000123222966) 
 Institute of Structural Biology, Helmholtz Munich, Molecular Targets and Therapeutics Center, Neuherberg, Germany (GRID:grid.6936.a); Technical University of Munich, TUM School of Natural Sciences, Department of Bioscience, Bavarian NMR Center, Garching, Germany (GRID:grid.6936.a) (ISNI:0000000123222966) 
 CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria (GRID:grid.418729.1) (ISNI:0000 0004 0392 6802); Sloan Kettering Institute, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952) 
 CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria (GRID:grid.418729.1) (ISNI:0000 0004 0392 6802); Medical University of Vienna, Institute of Artificial Intelligence, Center for Medical Data Science, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492) 
Pages
4504
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2851515441
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.